Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02713386 · ClinicalTrials.gov registry record · Phase 1
Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 1 study, sponsored by NRG Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 147
- Enrollment target
NCT02713386 is a Phase 1 study that has completed, run by NRG Oncology. The registered enrollment target is 147 participants.
The verdict
NCT02713386, a Phase 1 study, has completed, sponsored by NRG Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 147 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and the best dose of ruxolitinib phosphate when given together with paclitaxel and carboplatin and to see how well they work in treating patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ruxolitinib phosphate together with paclitaxel and carboplatin may be a better treatment for epithelial ovarian, fallopian tube, or primary peritoneal cancer compared to paclitaxel and carboplatin alone.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- PROCEDURE Therapeutic Conventional Surgery
- DRUG Ruxolitinib Phosphate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2016-11-14 |
| Est. Completion | 2024-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02713386
The ClinicalTrials.gov registry entry for NCT02713386 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NRG Oncology, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT02713386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02713386 about?
NCT02713386 is a clinical study titled "Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". This phase I/II trial studies the side effects and the best dose of ruxolitinib phosphate when given together with paclitaxel and carboplatin and to see how well they work in treating patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. Ruxolitinib phosphate m...
What is the current status of trial NCT02713386?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2016-11-14. Estimated completion is 2024-05-22.
What interventions are being tested in trial NCT02713386?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Therapeutic Conventional Surgery (PROCEDURE), Ruxolitinib Phosphate (DRUG).
Who is sponsoring clinical trial NCT02713386?
This trial is sponsored by NRG Oncology, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.